

Targeting HER2-Driven Disease Beyond the First Line: Antibody-Drug Conjugate Therapy in Gastrointestinal Cancers

TOOLKIT

Resources	Web Address
Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: An update. <i>World J Gastroenterol.</i> 2016;22(19):4619-4625.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4870069/
Arnold M, Abnet CC, Neale RE, et al. Global burden of 5 major types of gastrointestinal cancer. <i>Gastroenterology.</i> 2020;159(1):335-349.e15.	https://pubmed.ncbi.nlm.nih.gov/32247694/
Bang YJ, Giaccone G, Im SA, et al. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. <i>Ann Oncol.</i> 2017;28(4):855-861.	https://pubmed.ncbi.nlm.nih.gov/28119295/
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. <i>Lancet.</i> 2010;376(9742):687-697.	https://pubmed.ncbi.nlm.nih.gov/20728210/
Chung HC, Bang YJ, S Fuchs C, et al. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. <i>Future Oncol.</i> 2021;17(5):491-501.	https://pubmed.ncbi.nlm.nih.gov/33167735/
Clinicaltrials.gov. DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]. Last updated February 23, 2021.	https://clinicaltrials.gov/ct2/show/NCT03329690
Clinicaltrials.gov. Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-811). Last updated August 6, 2021.	https://clinicaltrials.gov/ct2/show/NCT03615326
Clinicaltrials.gov. Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy	https://clinicaltrials.gov/ct2/show/NCT04082364

Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY). Last updated May 3, 2021.	
De Cuyper A, Van Den Eynde M, Machiels JP. HER2 as a predictive biomarker and treatment target in colorectal cancer. <i>Clin Colorectal Cancer</i> . 2020;19(2):65-72.	https://pubmed.ncbi.nlm.nih.gov/32229076/
El Dika I, Ilson DH. Current and future therapies for targeting HER2 mutations in gastrointestinal cancer. <i>Expert Rev Anticancer Ther</i> . 2018;18(11):1085-1092.	https://pubmed.ncbi.nlm.nih.gov/30092682/
Ford H, Marshall A, Wadsley J, et al. COUGAR-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma. <i>J Clin Oncol</i> . 2013;31(4 suppl):LBA4.	https://ascopubs.org/action/showCitFormats?doi=10.1200/jco.2013.31.4_suppl.lba4
Fuchs CS, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial. <i>J Clin Oncol</i> . 2020;38:(15 suppl):4503.	https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.4503
Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. <i>Lancet</i> . 2014;383(9911):31-39.	https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)61719-5/fulltext
Gravalos C, Jimeno A. HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target. <i>Ann Oncol</i> . 2008;19(9):1523-1529.	https://pubmed.ncbi.nlm.nih.gov/18441328/
Hecht JR, Bang YJ, Qin SK, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC—A randomized phase III trial. <i>J Clin Oncol</i> . 2016;34(5):443-451.	https://ascopubs.org/doi/10.1200/JCO.2015.62.6598
Iwata H, Tamura K, Doi T, et al. Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts. <i>J Clin Oncol</i> . 2018;36(15 suppl):2501.	https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.2501
Janjigian YY, Kawazoe A, Yanez PE, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or	https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.4013

gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study.. <i>J Clin Oncol</i> . 2021;39(15 suppl):4013.	
Janjigian YY, Maron SB, Chatila WK, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: An open-label, single-arm, phase 2 trial. <i>Lancet Oncol</i> . 2020;21(6):821-831.	https://pubmed.ncbi.nlm.nih.gov/32437664/
Kang JH, Lee SI, Lim DH, et al. Salvage chemotherapy for pretreated gastric cancer: A randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. <i>J Clin Oncol</i> . 2012;30(13):1513-1518.	https://ascopubs.org/doi/pdf/10.1200/JCO.2011.39.4585
Kang YK, Shah MA, Ohtsu A, et al. A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC). <i>J Clin Oncol</i> . 2016;34(4 suppl):5.	https://ascopubs.org/doi/abs/10.1200/jco.2016.34.4_suppl.5
Kelly CM, Janjigian YY. The genomics and therapeutics of HER2-positive gastric cancer—from trastuzumab and beyond. <i>J Gastrointest Oncol</i> . 2016;7(5):750-762.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056254/
Kim ST, Banks KC, Pectasides E, et al. Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients. <i>Ann Oncol</i> . 2018;29(4):1037-1048.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913644/
Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. <i>J Clin Oncol</i> . 2010;28(16):2698-2704.	https://pubmed.ncbi.nlm.nih.gov/20421541/
Lee J, Ou SH. Towards the goal of personalized medicine in gastric cancer—time to move beyond HER2 inhibition. Part I: Targeting receptor tyrosine kinase gene amplification. <i>Discov Med</i> . 2013;15(85):333-341.	https://www.discoverymedicine.com/Jeeyun-Lee/2013/06/25/towards-the-goal-of-personalized-medicine-in-gastric-cancer-time-to-move-beyond-her2-inhibition-part-i-targeting-receptor-tyrosine-kinase-gene-amplification/
Mahato R, Tai W, Cheng K. Prodrugs for improving tumor targetability and efficiency. <i>Adv Drug Deliv Rev</i> . 2011;63(8):659-670.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132824/
Makiyama A, Sukawa Y, Kashiwada T, et al. Randomized, phase II study of trastuzumab	https://pubmed.ncbi.nlm.nih.gov/32208960/

beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT study). <i>J Clin Oncol</i> . 2020;38(17):1919-1927.	
Meric-Bernstam F, Beeram M, Mayordomo JI, et al. Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers. <i>J Clin Oncol</i> . 2018;36(15 suppl):2500.	https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.2500
Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. <i>Cancer Res</i> . 2001;61(12):4744-4749.	https://pubmed.ncbi.nlm.nih.gov/11406546/
Namikawa T, Shiga M, Ichikawa K, Kitagawa H, Kobayashi M, Hanazaki K. Metachronous liver and bone metastasis from small early gastric carcinoma without lymph node involvement: A case report. <i>Mol Clin Oncol</i> . 2013;1(2):249-252.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3956265/
National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Gastric Cancer, Version 4.2021.	https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1434
Petit AM, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. <i>Am J Pathol</i> . 1997;151(6):1523-1530.	https://pubmed.ncbi.nlm.nih.gov/9403702/
Raghav KPS, McDonough SL, Tan BR, et al. A randomized phase II study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: S1613. <i>J Clin Oncol</i> . 2018;36(15 suppl):TPS3620.	https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.TPS3620
Rüschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. <i>Virchows Arch</i> . 2010;457(3):299-307.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2933810/
Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic	https://pubmed.ncbi.nlm.nih.gov/27108243/

colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial. <i>Lancet Oncol.</i> 2016;17(6):738-746.	
Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. <i>Cancer Res.</i> 2009;69(24):9330-9336.	https://pubmed.ncbi.nlm.nih.gov/19934333/
Shah MA, Kang YK, Thuss-Patience PC, et al. Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer. <i>Gastric Cancer.</i> 2019;22(4):803-816.	https://pubmed.ncbi.nlm.nih.gov/30706247/
Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. <i>N Engl J Med.</i> 2020;382(25):2419-2430.	https://pubmed.ncbi.nlm.nih.gov/32469182/
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. <i>CA Cancer J Clin.</i> 2021;71(1):7-33.	https://pubmed.ncbi.nlm.nih.gov/33433946/
Siena S, Di Bartolomeo M, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): A multicentre, open-label, phase 2 trial. <i>Lancet Oncol.</i> 2021;22(6):779-789.	https://pubmed.ncbi.nlm.nih.gov/33961795/
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. <i>CA Cancer J Clin.</i> 2021;71(3):209-249.	https://pubmed.ncbi.nlm.nih.gov/33538338/
Taberero J, Hoff PM, Shen L, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): Final analysis of a double-blind, randomised, placebo-controlled phase 3 study. <i>Lancet Oncol.</i> 2018;19(10):1372-1384.	https://pubmed.ncbi.nlm.nih.gov/30217672/
Thuss-Patience PC, Kretschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). <i>Eur J Cancer.</i> 2011;47(15):2306-2314.	https://pubmed.ncbi.nlm.nih.gov/21742485/

<p>Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): An international randomised, open-label, adaptive, phase 2/3 study. <i>Lancet Oncol.</i> 2017;18(5):640-653.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/28343975/</p>
<p>Weisser NE, Wickman G, Abraham L, et al. Abstract 1005: The bispecific antibody zanidatamab's (ZW25's) unique mechanisms of action and durable anti-tumor activity in HER2-expressing cancers. <i>Cancer Res.</i> 2021;81(13 suppl):1005.</p>	<p>https://cancerres.aacrjournals.org/content/81/13_Supplement/1005</p>
<p>Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. <i>Lancet Oncol.</i> 2014;15(11):1224-1235.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/25240821/</p>
<p>Yamaguchi K, Bang Y, Iwasa S, et al. 1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study. <i>Ann Oncol.</i> 2020;31(suppl 4):S899-S900.</p>	<p>https://www.annalsofoncology.org/article/S0923-7534(20)41924-6/fulltext</p>
<p>zum Büschenfelde CM, Hermann C, Schmidt B, Peschel C, Bernhard H. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. <i>Cancer Res.</i> 2002;62(8):2244-2247.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/11956077/</p>